Vinorelbine - Pierre Fabre

Drug Profile

Vinorelbine - Pierre Fabre

Alternative Names: KW-2307; Navelbine; NVB; Vinorelbine ditartrate; Vinorelbine tartrate

Latest Information Update: 29 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS
  • Developer Amgen; Bristol-Myers Squibb; Centre Oscar Lambret; Pierre Fabre; UNICANCER; University of Washington
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer
  • Phase II Glioma; Mesothelioma
  • Phase I/II Solid tumours
  • No development reported Cervical cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 20 Jun 2018 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO) (NCT03518606)
  • 01 Jun 2018 Adverse events and efficacy data from phase II NAVoTRIAL-3 trial in Nono-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 08 May 2018 Pierre Fabre plans the phase I/II MOVIE trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in France (NCT03518606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top